Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) announced a share buyback plan, indicating confidence in its business outlook and intrinsic value, which has positively impacted its stock price [1] Group 1: Stock Performance - The stock price of Corning Jereh Pharmaceutical-B rose over 7% in the afternoon trading session, with a current increase of 5.06%, reaching HKD 10.18 [1] - The trading volume amounted to HKD 18.5499 million [1] Group 2: Share Buyback Announcement - The board of directors resolved on November 7 to repurchase ordinary shares from the open market, with a maximum buyback amount of HKD 30 million [1] - The board believes that the current trading price does not accurately reflect the company's intrinsic value [1] - This buyback is expected to benefit the company and create value for its shareholders [1] - In October, the company had already announced a plan to repurchase up to HKD 20 million in shares [1]

Core Viewpoint - The article discusses recent developments in the pharmaceutical industry, particularly focusing on new drug applications and innovations in cancer treatment, highlighting the competitive landscape and market potential for various companies involved in drug development [5][12][20]. Group 1: New Drug Applications - From May 24 to May 30, the National Medical Products Administration received applications for 9 new chemical drugs and biological products from 6 listed companies [5]. - Companies such as Heng Rui Medicine, Hansoh Pharmaceutical, and Kangfang Biotech each submitted 2 clinical applications, while others like Canaan and Bai Jie Shen Zhou submitted 1 application each [6]. Group 2: Key Innovations in Cancer Treatment - Kangning Jereh's KN035, a subcutaneous PD-L1 inhibitor, has been submitted for clinical trials, potentially becoming the first of its kind globally. It targets multiple indications, with 3 applications already submitted and 7 ongoing clinical studies [12][13]. - KN035 offers advantages over traditional intravenous methods, including better patient compliance and reduced costs, which could enhance its market share [13]. - The competitive landscape includes existing PD-L1 inhibitors like Merck's Atezolizumab and AstraZeneca's Durvalumab, with KN035 targeting different cancer types [14]. Group 3: Dual Antibody Developments - Kangfang Biotech's AK104, a PD-1/CTLA-4 dual-specific antibody, has received approval for clinical trials, with 13 indications currently in phase II trials [17]. - The dual antibody approach is gaining traction due to the limitations of existing PD-1/L1 therapies, which have low efficacy rates in solid tumors [18]. - The market for dual antibodies is expected to grow significantly, with 217 candidates in various clinical stages globally [19]. Group 4: COVID-19 Vaccine Developments - CanSino's inhaled COVID-19 vaccine is in phase II trials and is applying for emergency use, which could enhance public acceptance due to its non-invasive administration method [20][21]. - Sinovac has expanded the emergency use of its vaccine to children aged 3 and above, with positive safety and efficacy results from clinical trials [24][25].

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 17, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks [1]. Group 1: Buyback Details - China Feihe (06186) repurchased 10.81 million shares for a total of 47.19 million yuan, representing 1.532% of its total share capital [2]. - COSCO Shipping Holdings (01919) repurchased 3 million shares for 41.62 million yuan, accounting for 1.083% of its total share capital [2]. - Sinopec Limited (00386) repurchased 3.79 million shares for 16.73 million yuan, which is 0.120% of its total share capital [2]. Group 2: Other Notable Buybacks - Lianlian Digital (02598) repurchased 1.71 million shares for 13.67 million yuan, representing 2.608% of its total share capital [2]. - Linklogis Technology (09959) repurchased 2.65 million shares for 7.40 million yuan, accounting for 4.885% of its total share capital [2]. - Jitu Express (01519) repurchased 640,000 shares for 6.25 million yuan, which is 0.041% of its total share capital [2]. Group 3: Additional Companies - Mengniu Dairy (02319) repurchased 200,000 shares for 2.98 million yuan, representing 0.660% of its total share capital [2]. - Kangning Jereh Pharmaceutical (09966) repurchased 350,000 shares for 3.42 million yuan, accounting for 0.211% of its total share capital [3]. - Huajian Medical (01931) repurchased 593,000 shares for 3.64 million yuan, which is 0.660% of its total share capital [3].

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966.HK) has conducted a share buyback on November 17, purchasing 350,000 shares at a total cost of HKD 3.4198 million, indicating a strategic move to enhance shareholder value [1][2]. Group 1: Buyback Details - On November 17, the company repurchased 350,000 shares at prices ranging from HKD 9.640 to HKD 9.860 per share, with a closing price of HKD 9.790 on that day [1]. - The total trading volume for the stock on that day was HKD 15.6234 million [1]. - Year-to-date, the company has completed six buybacks, totaling 2.031 million shares and an aggregate expenditure of HKD 23.3849 million [2]. Group 2: Buyback Summary Table - The buyback details are as follows: - November 17: 350,000 shares at a maximum price of HKD 9.860 and a minimum price of HKD 9.640, costing HKD 3.4198 million - November 7: 560,000 shares at a maximum price of HKD 9.520 and a minimum price of HKD 9.240, costing HKD 5.2610 million - October 28: 320,000 shares at a maximum price of HKD 11.970 and a minimum price of HKD 11.530, costing HKD 3.7684 million - October 16: 400,000 shares at a maximum price of HKD 13.820 and a minimum price of HKD 13.520, costing HKD 5.4830 million - October 14: 293,000 shares at a maximum price of HKD 13.830 and a minimum price of HKD 13.030, costing HKD 3.9669 million - October 13: 108,000 shares at a maximum price of HKD 13.800 and a minimum price of HKD 13.690, costing HKD 1.4860 million [2].

Core Viewpoint - Corning Incorporated announced a share buyback of 350,000 shares for a total expenditure of HKD 3.4198 million, scheduled for November 17, 2025 [1] Group 1 - The company plans to repurchase shares, indicating confidence in its financial position and future prospects [1] - The total amount allocated for the buyback is approximately HKD 3.4198 million, reflecting a strategic move to enhance shareholder value [1] - The buyback involves 350,000 shares, which may influence the stock's liquidity and market perception [1]

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966.HK) announced a share buyback of 350,000 shares at a cost of HKD 3.42 million on November 17 [1] Group 1 - The company executed a buyback program, indicating confidence in its stock value [1] - The total expenditure for the buyback was HKD 3.42 million [1] - The number of shares repurchased was 350,000 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康寧傑瑞生物製藥 呈交日期： 2025年11月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 09966 | 說明 | 普通股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | 已發行股份（ ...

Group 1 - The Hong Kong battery sector continues to strengthen, with Longpan Technology rising over 25% [1] - Ruipu Lanjun increased by more than 10% [1] - Ganfeng Lithium rose by over 9% [1] - Zhongchuang Xinhang and Tianqi Lithium both saw increases of over 8% [1]

Core Viewpoint - Corning Jereh Pharmaceutical-B has conducted share buybacks, indicating a strategy to enhance shareholder value amidst stock price fluctuations [2] Buyback Summary - On November 7, the company repurchased 560,000 shares at a price range of HKD 9.240 to HKD 9.520, totaling HKD 5.261 million [2] - The stock closed at HKD 9.470 on the same day, reflecting a decline of 9.29%, with a total trading volume of HKD 84.0624 million [2] - Year-to-date, the company has completed five buyback transactions, repurchasing a total of 1.681 million shares for a cumulative amount of HKD 19.9651 million [2] Detailed Buyback Information - Buyback details include: - November 7: 560,000 shares at a maximum price of HKD 9.520 and a minimum of HKD 9.240, totaling HKD 5.261 million - October 28: 320,000 shares at a maximum price of HKD 11.970 and a minimum of HKD 11.530, totaling HKD 3.7684 million - October 16: 400,000 shares at a maximum price of HKD 13.820 and a minimum of HKD 13.520, totaling HKD 5.483 million - October 14: 293,000 shares at a maximum price of HKD 13.830 and a minimum of HKD 13.030, totaling HKD 3.9669 million - October 13: 108,000 shares at a maximum price of HKD 13.800 and a minimum of HKD 13.690, totaling HKD 1.486 million [2]

Core Viewpoint - The company, Corning Incorporated, has announced a decision by its board to repurchase up to HKD 30 million of its ordinary shares from the open market, indicating a belief that the current share price does not accurately reflect its intrinsic value [1] Group 1 - The board believes that the share repurchase will demonstrate confidence in the company's business outlook and prospects [1] - The company asserts that the current financial resources are sufficient to support the proposed share buyback while maintaining a robust financial position [1]